October 2nd 2023
European Educational Workshop on MRD in AML and CLL
We thank our sponsors for the generous support of the workshop.

Detection of measurable residual disease (MRD) is an important prognostic biomarker for refining risk assessment and predicting relapse in acute myeloid leukemia (AML). These comprehensive guidelines and recommendations with best practices for consistent and accurate identification and detection of MRD may aid in making effective AML treatment decisions.